山河药辅 (300452.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	956.3M	942.8M	882.6M	839.3M	704.5M
Cost of Revenue	652.8M	643.4M	608.6M	573.3M	494.8M
Gross Profit	303.5M	299.4M	273.9M	266.0M	209.8M
Operating Expenses
R&D Expense	40.6M	42.3M	41.0M	42.0M	34.4M
SG&A Expense	—	—	—	—	—
General & Admin Expense	38.1M	37.8M	34.8M	32.1M	28.4M
Selling & Marketing Expense	31.1M	30.6M	29.4M	28.5M	23.3M
Other Expenses	—	—	—	—	—
Total Operating Expenses	134.7M	133.6M	124.6M	111.8M	90.8M
Cost and Expenses	787.5M	777.0M	733.2M	685.1M	585.6M
Operating Income (EBIT)	200.4M	199.1M	143.3M	185.4M	136.3M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	199.9M	198.7M	142.4M	185.8M	136.4M
Income Tax Expense	25.9M	25.5M	21.8M	21.2M	5.5M
Bottom Line
Net Income	176.4M	176.6M	119.4M	161.5M	130.7M
Earnings from Cont. Ops	174.0M	173.2M	120.5M	164.6M	130.9M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	176.4M	176.6M	119.4M	161.5M	130.7M
Per Share
Basic EPS	CN¥0.75	CN¥0.75	CN¥0.51	CN¥0.69	CN¥0.56
Diluted EPS	CN¥0.75	CN¥0.73	CN¥0.51	CN¥0.67	CN¥0.56
Revenue Per Share	CN¥4.06	CN¥4.01	CN¥3.77	CN¥3.58	CN¥3.02
Shares
Basic Shares Outstanding	235.3M	235.4M	234.2M	234.1M	233.4M
Diluted Shares Outstanding	235.3M	235.4M	234.2M	234.1M	233.4M
Profitability Metrics
EBITDA	—	253.5M	194.4M	224.5M	172.5M
D&A	—	54.4M	51.2M	39.1M	36.2M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026